May 2025 in “Journal of Inflammation Research” In this case report, a 28-year-old Chinese man with severe dissecting cellulitis of the scalp experienced nodules resolution and hair regrowth after treatment with ixekizumab and tofacitinib, marking the first reported use of this drug combination for the condition.
April 2026 in “Dermatology and Therapy” This study reviews the efficacy and safety of advanced therapies like TNFα inhibitors and IL-17/IL-23 inhibitors for dissecting cellulitis of the scalp, finding TNFα inhibitors particularly effective for severe or refractory cases, although prospective validation is needed for early intervention benefits.
1 citations
,
September 2023 in “Dermatology and therapy” This review explores the efficacy and safety of treatments for dissecting cellulitis of the scalp, revealing a predominance of case reports and series, and concludes that randomized controlled trials are needed for better evidence-based therapies.
March 2026 in “Biomedicines” This review synthesizes current evidence on therapies for dissecting cellulitis of the scalp, noting that biologics show promise for treatment-resistant cases, though systemic retinoids remain the first-line therapy.
October 2024 in “TURKDERM” Hair transplantation can lead to rare scalp complications, requiring careful follow-up and treatment.